25 February 2016 - Allergan plc today announced that the Company has received approval from the U.S. FDA to market Aczone (dapsone) 7.5% topical gel, a new prescription topical treatment for acne in patients 12 years of age and older.

For more details, go to: http://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-approval-of-aczone-dapsone